Results 121 to 130 of about 22,140 (237)

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Mechanism‐informed machine learning for individualized tacrolimus dose adjustment in the early post‐kidney transplant period

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus dosing in the early post‐kidney transplant period is challenging due to a narrow therapeutic index and substantial interindividual pharmacokinetic (PK) variability. This study aimed to develop and validate mechanism‐informed machine learning (ML) models to support individualized tacrolimus dosing during this critical period ...
Hui Yu, Zihan Qin, Logan S. Smith, Jeong M. Park, Hao‐Jie Zhu   +4 more
wiley   +1 more source

Anesthesia-induced developmental neurotoxicity in the setting of systemic inflammation: the role of microglia. [PDF]

Exp Biol Med (Maywood)
Useinovic N, Newson A, Near M, Maksimovic S, Volvovitz B, Quillinan N, Jevtovic-Todorovic V.   +6 more
europepmc   +1 more source

Developmental neurotoxicity and stem cells

Folia Pharmacologica Japonica, 2015
Shigeru, Yamada, Yasunari, Kanda
openaire   +3 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Statement on the testing strategy and timelines for the assessment of developmental neurotoxicity and endocrine disruption properties of acetamiprid in the context of the review of the approval of the active substance. [PDF]

EFSA J
European Food Safety Authority (EFSA).
europepmc   +1 more source

Pluripotent Stem Cell-derived Dopaminergic Neurons for Studying Developmental Neurotoxicity. [PDF]

Stem Cell Rev Rep, 2023
Kreutz A, Hu G, Tokar E.
europepmc   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon, Chengsheng Ju, Kenneth K. C. Man, Rebecca Roylance, Diego Ottaviani, Chiara Creed, Michal Sladkowski, Alec Wisner, Li Wei, Pinkie Chambers   +9 more
wiley   +1 more source

Anesthesia-induced Developmental Neurotoxicity in Pediatric Population. [PDF]

J Surg Res (Houst)
Chaudhary F, Agrawal DK.
europepmc   +1 more source

Non-disclosure of developmental neurotoxicity studies obstructs the safety assessment of pesticides in the European Union. [PDF]

Environ Health, 2023
Mie A, Rudén C.
europepmc   +1 more source